Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
96.73 USD | +0.89% | +0.68% | -4.20% |
Mar. 28 | NOVARTIS AG : Barclays gives a Sell rating | ZD |
Mar. 25 | NOVARTIS AG : Berenberg remains Neutral | ZD |
Business Summary
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Number of employees: 76,057
Sales per Business
CHF in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Established Brands
30.0
%
| - | - | 12,238 | 30.0 % | - |
Oncology
29.9
%
| - | - | 12,213 | 29.9 % | - |
Immunology
17.2
%
| - | - | 7,008 | 17.2 % | - |
Cardiovascular, Renal and Metabolic
14.1
%
| - | - | 5,743 | 14.1 % | - |
Neuroscience
8.9
%
| - | - | 3,633 | 8.9 % | - |
Sales per region
CHF in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
39.5
%
| 16,860 | 34.9 % | 16,139 | 39.5 % | -4.28% |
Europe
18.9
%
| 10,469 | 21.7 % | 7,704 | 18.9 % | -26.41% |
Asia/Africa/Australasia
9.1
%
| 4,975 | 10.3 % | 3,700 | 9.1 % | -25.63% |
Germany
7.4
%
| 4,086 | 8.5 % | 3,026 | 7.4 % | -25.94% |
China
7.2
%
| 2,987 | 6.2 % | 2,936 | 7.2 % | -1.73% |
Canada and Latin America
7.0
%
| 3,709 | 7.7 % | 2,854 | 7.0 % | -23.04% |
Japan
4.2
%
| 2,106 | 4.4 % | 1,729 | 4.2 % | -17.90% |
France
3.8
%
| 2,156 | 4.5 % | 1,572 | 3.8 % | -27.09% |
Switzerland
2.9
%
| 926 | 1.9 % | 1,175 | 2.9 % | +26.88% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 04-12-31 | |
Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
Steffen Lang
COO | Chief Operating Officer | 57 | 17-03-31 |
Klaus Moosmayer
CMP | Compliance Officer | 56 | 18-11-30 |
Samir Shah
IRO | Public Communications Contact | 63 | 03-12-31 |
Simon Brown
PRN | Corporate Officer/Principal | - | 13-07-31 |
Kees Roks
AUD | Comptroller/Controller/Auditor | 61 | 22-04-30 |
Linda Kanitra
PRN | Corporate Officer/Principal | - | - |
Robert Kowalski
HRO | Human Resources Officer | 56 | 21-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
Chairman | 68 | 12-12-31 | |
John Young
BRD | Director/Board Member | 60 | 23-03-06 |
Bridgette Heller
BRD | Director/Board Member | 63 | 20-02-27 |
Ton Büchner
BRD | Director/Board Member | 59 | 15-12-31 |
Charles Sawyers
BRD | Director/Board Member | 65 | 12-12-31 |
Nancy Andrews
BRD | Director/Board Member | 66 | 14-12-31 |
Patrice Bula
BRD | Director/Board Member | 68 | 19-02-27 |
Frans van Houten
BRD | Director/Board Member | 63 | 17-02-27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 2,277,477,752 | 1,866,336,959 ( 81.95 %) | 233,443,766 ( 10.25 %) | 81.95 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
NOVARTIS AG 6.37% | 145,083,991 | 6.37% | 14,744,836,677 $ |
SANDOZ GROUP AG 4.30% | 18,524,209 | 4.30% | 577,678,384 $ |
NOVARTIS INDIA LIMITED 70.68% | 17,450,680 | 70.68% | 198,486,303 $ |
ERASCA, INC. 8.15% | 12,307,692 | 8.15% | 29,292,307 $ |
THIRD HARMONIC BIO, INC. 6.55% | 2,642,762 | 6.55% | 26,797,607 $ |
5,908,089 | 6.18% | 23,396,032 $ | |
OCULIS HOLDING AG 4.68% | 1,713,521 | 4.68% | 20,390,900 $ |
MOLECULAR PARTNERS AG 4.78% | 1,739,130 | 4.78% | 7,712,572 $ |
413,577 | 6.51% | 7,651,175 $ | |
GAMIDA CELL LTD. 3.27% | 4,336,759 | 3.27% | 1,561,233 $ |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. |
Pharmaceuticals: Major
|
Novartis BioVenturesAG
Novartis BioVenturesAG Investment ManagersFinance Part of Novartis AG, Novartis BioVenturesAG is an alternative investment manager. The private company is based in Basel, Switzerland. |
Investment Managers
|
Pharmaceuticals: Major
| |
Novartis Securities Investment Ltd.
Novartis Securities Investment Ltd. Investment ManagersFinance Part of Novartis AG, Novartis Securities Investment Ltd. is an investment bank that offers investment advice. The private company is located in Bermuda. |
Investment Managers
|
EBEWE Pharma Ges.m.b.H. Nfg.KG
EBEWE Pharma Ges.m.b.H. Nfg.KG Pharmaceuticals: MajorHealth Technology EBEWE Pharma Ges.m.b.H. Nfg.KG engages in the development and manufacture of injectable pharmaceutical specialties. The firm offers therapy solutions for colon, lung, breast, and prostate cancer. It also specializes in drug and pharmaceutical development, as well as preclinical studies. The company was founded in 1934 and is headquartered in Unterach am Attersee, Austria. |
Pharmaceuticals: Major
|
Novartis Capital Corp.
Novartis Capital Corp. Finance/Rental/LeasingFinance Novartis Capital Corp. engages in the manufacture of pharmaceutical products. The company is headquartered in East Hanover, NJ. |
Finance/Rental/Leasing
|
Novartis Finance SA
|
Finance/Rental/Leasing
|
Sandoz GmbH
Sandoz GmbH Pharmaceuticals: MajorHealth Technology Sandoz GmbH manufactures generic pharmaceuticals and biotechnological drugs. Its products includes bio-similars, inhalers, patches, injectables, and oral solids. The company was founded in 1946 and is headquartered in Kundl, Austria. |
Pharmaceuticals: Major
|
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. |
Pharmaceuticals: Major
|
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+0.74% | 209B | |
-6.05% | 205B | |
-3.61% | 157B | |
-1.28% | 152B |
- Stock
- Equities
- Stock Novartis AG
- Stock Novartis AG - Nyse
- Company Novartis AG